View in EDS HTML Full Text PDF Full Text

Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study.

Saved in:
Bibliographic Details
Title: Real-World Evidence of Regorafenib Dose Escalation Versus Fixed Dosing in Refractory Metastatic Colorectal Cancer: Results from the ReTrITA Study.
Authors: Signorelli, Carlo1 (AUTHOR) carlo.signorelli@asl.vt.it, Basso, Michele2 (AUTHOR), Calegari, Maria Alessandra2,3 (AUTHOR), Anghelone, Annunziato2,4 (AUTHOR), Passardi, Alessandro3,5 (AUTHOR), Gallio, Chiara3,6 (AUTHOR), Bittoni, Alessandro3,7 (AUTHOR), Lucchetti, Jessica4,8 (AUTHOR), Angotti, Lorenzo4,9 (AUTHOR), Di Giacomo, Emanuela4,10 (AUTHOR), Zurlo, Ina Valeria5,11 (AUTHOR), Morelli, Cristina6,12 (AUTHOR), Dell'Aquila, Emanuela7,13 (AUTHOR), Artemi, Adele7,14 (AUTHOR), Gemma, Donatello8,15 (AUTHOR), Emiliani, Alessandra9,16 (AUTHOR), Ribelli, Marta9,17 (AUTHOR), Corsi, Domenico Cristiano9,18 (AUTHOR), Arrivi, Giulia10,19 (AUTHOR), Mazzuca, Federica10,20 (AUTHOR)
Source: Cancers. Oct2025, Vol. 17 Issue 20, p3316. 21p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:20726694
DOI:10.3390/cancers17203316